<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11174482
   </pmid>
   <datecreated>
    <year>
     2001
    </year>
    <month>
     02
    </month>
    <day>
     22
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2001
    </year>
    <month>
     06
    </month>
    <day>
     28
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0002-9378
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       184
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2001
       </year>
       <month>
        Jan
       </month>
      </pubdate>
     </journalissue>
     <title>
      American journal of obstetrics and gynecology
     </title>
     <isoabbreviation>
      Am. J. Obstet. Gynecol.
     </isoabbreviation>
    </journal>
    <articletitle>
     An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms.
    </articletitle>
    <pagination>
     <medlinepgn>
      70-5
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      Our purpose was to evaluate the use of transvaginal ultrasonography for the detection of endometrial disease in a population of postmenopausal women who were without symptoms.
     </abstracttext>
     <abstracttext label="STUDY DESIGN" nlmcategory="METHODS">
      Postmenopausal women were screened for potential inclusion in 2 multicenter, double-blind, placebo-controlled studies of 2 years' duration to evaluate the safety and efficacy of idoxifene in the prevention of osteoporosis. Baseline endometrial evaluation was performed by transvaginal ultrasonography and aspiration biopsy of the endometrium.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      A total of 1926 women were screened by transvaginal ultrasonography, and 1833 of them had endometrial thickness &lt; or =6 mm. Five cases of endometrial abnormality (adenocarcinoma [n = 1] and atypical hyperplasia [n = 4]) were detected in the 1750 women from this cohort who underwent biopsy. The negative predictive value was &gt;99%. One case of adenocarcinoma was detected in the 42 women who had endometrial thickness &gt;6 mm and underwent biopsy. However, the sampling rate (45%) of women with endometrial thickness &gt;6 mm was too low for confidence in the positive predictive value of 2%.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Despite a high negative predictive value, transvaginal ultrasonography may not be an effective screening procedure for detection of endometrial abnormality in untreated postmenopausal women who are without symptoms.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Fleischer
      </lastname>
      <forename>
       A C
      </forename>
      <initials>
       AC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wheeler
      </lastname>
      <forename>
       J E
      </forename>
      <initials>
       JE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lindsay
      </lastname>
      <forename>
       I
      </forename>
      <initials>
       I
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hendrix
      </lastname>
      <forename>
       S L
      </forename>
      <initials>
       SL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Grabill
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kravitz
      </lastname>
      <forename>
       B
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       MacDonald
      </lastname>
      <forename>
       B
      </forename>
      <initials>
       B
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Am J Obstet Gynecol
    </medlineta>
    <nlmuniqueid>
     0370476
    </nlmuniqueid>
    <issnlinking>
     0002-9378
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Placebos
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      10540-29-1
     </registrynumber>
     <nameofsubstance>
      Tamoxifen
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      116057-75-1
     </registrynumber>
     <nameofsubstance>
      pyrrolidino-4-iodotamoxifen
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adenocarcinoma
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      ultrasonography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Biopsy, Needle
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Endometrial Hyperplasia
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      ultrasonography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Endometrial Neoplasms
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      ultrasonography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Endometrium
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      ultrasonography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Osteoporosis, Postmenopausal
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Placebos
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Postmenopause
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sensitivity and Specificity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tamoxifen
     </descriptorname>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Uterine Diseases
     </descriptorname>
     <qualifiername majortopicyn="Y">
      ultrasonography
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2001
     </year>
     <month>
      2
     </month>
     <day>
      15
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2001
     </year>
     <month>
      6
     </month>
     <day>
      29
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2001
     </year>
     <month>
      2
     </month>
     <day>
      15
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11174482
    </articleid>
    <articleid idtype="pii">
     S0002-9378(01)73958-0
    </articleid>
    <articleid idtype="doi">
     10.1067/mob.2001.111088
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

